List of Excipients in Branded Drug NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND HEADACHE

Generic Drugs Containing NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND HEADACHE

Company	Ingredient	NDC	Excipient
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	CROSCARMELLOSE SODIUM
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	FERRIC OXIDE YELLOW
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	HYPROMELLOSE
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	HYPROMELLOSE 2208
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	HYPROMELLOSE 2910
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	LACTOSE MONOHYDRATE
Aurohealth LLC	naproxen sodium and pseudoephedrine hydrochloride	58602-832	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE SINUS AND HEADACHE?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE
1	HYPROMELLOSE 2208
1	HYPROMELLOSE 2910
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE

Naproxen Sodium and Pseudoephedrine Hydrochloride Sinus and Headache: Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Naproxen sodium 220 mg plus pseudoephedrine hydrochloride 120 mg is a mature OTC combination for sinus congestion, headache, and pain. Its commercial value depends less on new active-ingredient exclusivity and more on tablet engineering, 12-hour release performance, brand trust, retail execution, and regulatory control of pseudoephedrine sales. The strongest formulation opportunity is a robust bilayer or controlled-release matrix tablet that delivers naproxen sodium rapidly while releasing pseudoephedrine hydrochloride over approximately 12 hours.

What is the naproxen sodium and pseudoephedrine hydrochloride product?

The combination generally contains:

Component	Typical strength	Functional role
Naproxen sodium	220 mg	Analgesic and anti-inflammatory
Pseudoephedrine hydrochloride	120 mg	Systemic nasal decongestant
Dosage form	12-hour extended-release caplet or tablet	Sustained decongestant effect with pain relief
Administration	Usually one tablet every 12 hours	Maximum commonly labeled dose: two tablets per 24 hours

Aleve-D Sinus & Headache is the principal U.S. reference product associated with this active-ingredient combination. The FDA labeling identifies naproxen sodium as the analgesic and pseudoephedrine hydrochloride as the nasal decongestant. The label also carries NSAID gastrointestinal, cardiovascular, renal, pregnancy, and drug-interaction warnings, together with pseudoephedrine restrictions and stimulant-related cautions. (DailyMed, 2024a)

The product addresses two linked consumer symptoms: congestion and headache or facial pain. That combination supports premium positioning over single-ingredient naproxen or pseudoephedrine products.

What excipient strategy is required for a 12-hour combination tablet?

The formulation must solve a release-profile conflict. Naproxen sodium is generally intended to provide relatively rapid analgesic action, while pseudoephedrine hydrochloride must be released gradually to support 12-hour decongestant activity.

A single uncontrolled immediate-release tablet would create an unfavorable exposure profile. A single highly retarding matrix could delay naproxen onset and reduce the consumer-perceived benefit. The preferred platform is a bilayer tablet or a multiparticulate system with separate release functions.

Recommended release architecture

Layer or phase	Active ingredient	Release objective	Excipient strategy
Immediate-release phase	Naproxen sodium	Rapid dissolution and analgesic onset	Microcrystalline cellulose, croscarmellose sodium, low-viscosity binder, magnesium stearate
Extended-release phase	Pseudoephedrine hydrochloride	Approximately 12-hour release	Hypromellose matrix, ethylcellulose, polymer coating, or a combination
Film coat	Both phases	Protection, identification, swallowability	Hypromellose, polyethylene glycol, titanium dioxide or permitted colorants
Processing aids	Both phases	Flow, compression, lubrication	Colloidal silicon dioxide, magnesium stearate, talc where justified

A bilayer tablet gives the developer the best control over dissolution and compressibility. It also creates a more defensible manufacturing process than a conventional blend because layer weight, compression force, interface integrity, and release behavior can be controlled independently.

Immediate-release naproxen layer

Naproxen sodium is highly water soluble relative to naproxen free acid, which supports rapid dissolution. The immediate-release layer should prioritize:

• Low tablet disintegration time
• Minimal hydrophobic lubricant effect
• Adequate mechanical strength
• Consistent content uniformity
• Low sensitivity to humidity
• Acceptable mouthfeel if the tablet is chewed or split unintentionally

Microcrystalline cellulose is a practical primary filler and dry binder. Croscarmellose sodium can accelerate disintegration, but its concentration must be balanced against tablet strength and the risk of over-expansion at the bilayer interface. Povidone or copovidone can improve granule strength where wet granulation is used.

Magnesium stearate should be optimized rather than maximized. Excessive lubrication can slow wetting and dissolution, particularly in a high-dose tablet. A short lubrication time and controlled specific surface area are important process variables.

Extended-release pseudoephedrine layer

Pseudoephedrine hydrochloride is a relatively high-dose, water-soluble active. Water-soluble actives can generate rapid initial release from hydrophilic matrices unless polymer loading and tablet geometry are carefully controlled.

Suitable approaches include:

1. Hydrophilic hypromellose matrix with controlled polymer concentration.
2. Hydrophobic polymer matrix using ethylcellulose or comparable release-retarding excipients.
3. Coated granules or pellets compressed into a tablet.
4. Bilayer architecture combining a matrix layer with a functional film coat.
5. Osmotic or membrane-controlled delivery, although this is likely to be less attractive for a low-margin OTC product.

Hypromellose is usually the most commercially practical approach because it is widely accepted, scalable, and available from multiple suppliers. Higher-viscosity grades can extend release but may impair compression and increase tablet size. Lower-viscosity grades can improve manufacturability but may require higher polymer loading.

A coated multiparticulate design can reduce sensitivity to tablet geometry and improve release reproducibility. It also reduces the risk that a single tablet fracture will cause a large pseudoephedrine dose release. The tradeoff is higher process complexity, greater coating-solvent or aqueous-coating requirements, and increased cost.

Which excipients create the largest technical and regulatory risks?

The highest risks arise from release control, excipient compatibility, and label-supported inactive ingredients.

Release-modifying polymers

Polymer grade is a critical material attribute. Viscosity, particle size, substitution pattern, and moisture content can materially affect pseudoephedrine dissolution. A change between suppliers may require comparative dissolution work and potentially regulatory documentation.

Lubricants and glidants

Magnesium stearate can slow dissolution if over-lubrication occurs. Colloidal silicon dioxide can improve flow but may alter compactibility and blend segregation. Talc may assist processing and coating but must be justified in the final formulation.

Sweeteners and flavors

These are generally unnecessary for a swallowed caplet. Their commercial value is limited unless the product is redesigned as a chewable, orally disintegrating, or liquid formulation. A flavor system can complicate stability because volatile components may migrate or interact with coatings.

Colorants and titanium dioxide

Color differentiation has retail value, particularly for a branded sinus product. Titanium dioxide and synthetic colors must comply with current jurisdictional requirements. A clean-label version could use iron oxides or omit color, but the resulting appearance may weaken product recognition.

Film-coating systems

A thin hypromellose film can improve swallowing and protect the tablet from moisture. The coating must not materially delay naproxen dissolution or interfere with pseudoephedrine release. Polyethylene glycol plasticizers can improve flexibility but may increase moisture transmission if not balanced with the coating system.

What formulation patents protect this product category?

The original active ingredients are long-established and do not provide meaningful composition-of-matter exclusivity. Commercial protection is more likely to arise from:

• Bilayer tablet architecture
• Controlled-release pseudoephedrine matrix systems
• Coated pseudoephedrine particles
• Specific dissolution profiles
• Tablet geometry and layer-interface controls
• Manufacturing processes
• Packaging that limits moisture uptake
• Abuse-deterrent or tamper-resistant pseudoephedrine handling
• Method-of-use claims covering combined relief of sinus congestion and headache

The strongest patent claims would need to distinguish the product from earlier pseudoephedrine extended-release tablets and from separate administration of naproxen and pseudoephedrine. Broad claims to the active-ingredient combination are vulnerable because both ingredients and their therapeutic uses are old.

A new entrant should expect formulation patents to have limited remaining life if the target is a legacy product. The practical barrier is more likely to be development cost, FDA compliance, bioequivalence, and retail access than blocking patent rights.

What is the FDA regulatory and Orange Book status?

The combination is an OTC drug product rather than a conventional prescription NDA product. Naproxen sodium and pseudoephedrine hydrochloride are governed through FDA OTC regulatory pathways, including the applicable analgesic and internal nasal decongestant requirements under 21 C.F.R. Parts 330, 331, and 341, as applicable. (Electronic Code of Federal Regulations, 2024)

Orange Book implications

The Orange Book is primarily relevant to approved prescription drug products and their abbreviated new drug applications. An OTC monograph product generally does not have the same Orange Book patent-listing structure as a prescription NDA product.

That means a generic or private-label entrant typically does not rely on a conventional Paragraph IV strategy against an Orange Book-listed patent estate. The competitive process instead centers on:

• Compliance with the applicable OTC monograph or FDA order
• Product-specific FDA registration and listing obligations
• Labeling conformity
• Quality and manufacturing controls
• Demonstration of equivalent performance where required
• Patent clearance for any surviving formulation or process claims

A branded product may still assert non-Orange Book patents in district court or before the International Trade Commission. Those disputes would not necessarily trigger the automatic 30-month stay associated with an ANDA Paragraph IV certification.

When does this product lose exclusivity?

The active ingredients have been off patent for many years. Any meaningful exclusivity tied to the original combination or extended-release concept is likely expired or commercially weak in the United States.

Exclusivity element	Commercial status
Naproxen sodium active ingredient	Mature, no meaningful composition-of-matter exclusivity
Pseudoephedrine hydrochloride active ingredient	Mature, no meaningful composition-of-matter exclusivity
Combination concept	Vulnerable to prior-art challenges
12-hour release concept	Potentially protected only by narrow formulation claims
Brand name and trade dress	May remain commercially valuable
OTC monograph compliance	Regulatory requirement, not patent exclusivity
Pseudoephedrine retail controls	Operational barrier, not exclusivity

The key commercial distinction is between legal exclusivity and executional advantage. The product can retain pricing power through brand recognition, shelf placement, packaging, and reliable 12-hour performance even without a blocking patent.

What generic entry risks exist for naproxen-pseudoephedrine products?

Generic entry risk is high at the active-ingredient level and moderate at the dosage-form level.

High-risk areas for the incumbent

• Private-label substitution by mass retailers
• Store-brand versions using the same strengths
• Price compression in pharmacy and club channels
• Retailer control of shelf placement
• E-commerce comparison shopping
• Seasonal switching during cold and allergy periods

Barriers facing an entrant

• Developing a reproducible 12-hour pseudoephedrine dissolution profile
• Demonstrating consistent naproxen release
• Controlling tablet size and swallowability
• Managing pseudoephedrine procurement and recordkeeping
• Meeting FDA manufacturing and stability requirements
• Securing retail distribution
• Complying with state-level pseudoephedrine restrictions

A generic does not need to replicate every inactive ingredient. It must achieve the required quality, performance, labeling, and regulatory outcome. This creates an opportunity to reduce cost through excipient substitution, direct compression, or a lower-cost coating system.

How do pseudoephedrine controls affect commercial opportunity?

Pseudoephedrine is subject to federal retail purchase limits, identification requirements, sales-record obligations, and behind-the-counter controls under the Combat Methamphetamine Epidemic Act. State requirements can be stricter. (U.S. Drug Enforcement Administration, 2024)

These controls affect product economics in four ways:

1. They limit frictionless e-commerce fulfillment.
2. They increase retailer compliance costs.
3. They reduce impulse purchasing.
4. They favor established brands with strong pharmacy distribution.

A manufacturer can improve commercial performance through compliant serialization, retailer-integrated sales-limit controls, package formats that reduce diversion risk, and clear pharmacy-channel merchandising.

The restrictions also create a strategic barrier against small entrants. A company with a technically equivalent tablet may still struggle to achieve national distribution because retailers must manage pseudoephedrine compliance at the point of sale.

What commercial opportunities exist for this product?

Private-label and retailer-exclusive products

The most immediate opportunity is a store-brand equivalent in a 12-hour caplet. The target customer is a retailer seeking a lower-price alternative to branded sinus products. Margin depends on tablet manufacturing cost, packaging, retailer margin, and pseudoephedrine compliance overhead.

Premium formulation

A premium product could differentiate through:

• Smaller caplet size
• Faster naproxen onset with maintained pseudoephedrine duration
• Lower tablet weight
• Improved swallowability
• Gluten-free or lactose-free positioning where supportable
• Reduced colorant use
• Moisture-protective packaging
• Unit-dose blister packaging

Any release or onset claim must be supported by comparative dissolution, clinical evidence where required, and compliant labeling.

Seasonal packaging

Sinus and headache demand is seasonal. Multipacks, travel packs, and pharmacy-counter packaging can improve unit economics. Cartons with 10, 20, or 24 tablets can target different retail channels. Blister packaging can reduce moisture exposure and improve dose tracking but usually costs more than bottles.

Dual-SKU strategy

A manufacturer could offer:

• Naproxen sodium alone for pain
• Pseudoephedrine alone for congestion
• The combination product for consumers seeking both effects

This creates a portfolio around the same consumer need while allowing retailers to segment price and indication.

International licensing

International opportunity is jurisdiction-specific because pseudoephedrine status varies significantly. Some markets permit OTC sales, some impose pharmacy-only controls, and others restrict or prohibit oral pseudoephedrine. A licensing strategy should separate:

• Formulation rights
• Manufacturing rights
• Brand rights
• Local regulatory sponsorship
• Pseudoephedrine procurement and distribution rights

A U.S. formulation may require reformulation in markets with different monograph requirements, maximum strengths, warning language, or controlled-substance rules.

How does naproxen-pseudoephedrine compare with competing sinus products?

Product type	Pain relief	Decongestion	Duration	Main commercial advantage
Naproxen sodium alone	Strong	None	Typically shorter analgesic interval	Simple pain positioning
Pseudoephedrine alone	None	Strong	Often 12 hours in extended-release form	Lower active-ingredient complexity
Ibuprofen-pseudoephedrine	Strong	Strong	Often shorter or multiple daily doses	Familiar NSAID brand architecture
Acetaminophen-pseudoephedrine	Analgesic and antipyretic	Strong	Depends on formulation	Lower NSAID-specific warning burden
Phenylephrine combinations	Analgesic	Limited oral decongestant value under current FDA review	Variable	Easier retail availability in some channels
Naproxen-pseudoephedrine	Long-acting analgesia plus decongestion	Strong	Approximately 12 hours	Differentiated dual-symptom coverage

FDA has questioned the effectiveness of oral phenylephrine as a nasal decongestant at the standard OTC dose, creating a potential positioning advantage for pseudoephedrine-containing products. That advantage is constrained by pseudoephedrine sales controls. (U.S. Food and Drug Administration, 2023)

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barrier is not active-ingredient synthesis. It is reproducible controlled release at commercial scale.

Critical process variables include:

• Polymer hydration and distribution
• Granule moisture
• Compression force
• Bilayer interface strength
• Coating weight gain
• Lubrication time
• Blend segregation
• Tablet hardness and friability
• Dissolution across multiple pH conditions
• Stability under elevated temperature and humidity

A controlled-release tablet with a robust dissolution profile can create practical differentiation even where formal patent protection is narrow. The manufacturer should use design-of-experiments work to establish a dissolution design space and define critical material attributes for each polymer grade.

The most useful patent strategy would focus on narrow, technically defensible claims covering the release architecture and manufacturing process. Patent claims should avoid relying solely on the known active-ingredient combination.

What generic launch scenarios are most likely?

Scenario 1: Low-cost direct competitor

A private-label manufacturer launches a conventional 12-hour tablet with a similar release profile and a lower retail price. This is the most likely competitive scenario.

Scenario 2: Premium smaller-tablet product

A developer uses coated multiparticulates or a high-performance matrix to reduce tablet size and improve swallowing. The product targets older adults and consumers who avoid large caplets.

Scenario 3: Channel-specific package

A manufacturer develops compliant blister packs for pharmacy and travel channels. The product competes through package format rather than formulation innovation.

Scenario 4: Combination replacement

A retailer shifts shelf space toward acetaminophen-pseudoephedrine or ibuprofen-pseudoephedrine products. The risk is highest if consumers prioritize lower price or lower NSAID gastrointestinal risk over longer naproxen duration.

How strong is the patent estate?

The patent estate for the active ingredients is weak because the compounds and therapeutic uses are mature. A product-specific estate may be moderate only if it contains:

• A genuinely distinctive controlled-release system
• A narrow dissolution range tied to clinical performance
• A layered or multiparticulate manufacturing process
• A novel stability or abuse-deterrence solution
• Enforceable claims with meaningful geographic coverage

For a legacy naproxen-pseudoephedrine product, regulatory know-how, manufacturing scale, brand equity, and retail relationships are more important than patent exclusivity.

Key Takeaways

• The commercial product is typically a 220 mg naproxen sodium and 120 mg pseudoephedrine hydrochloride 12-hour tablet.
• A bilayer or multiparticulate formulation is preferable to an uncontrolled single-phase matrix.
• Immediate-release naproxen and extended-release pseudoephedrine should be engineered as separate release domains.
• Hypromellose, ethylcellulose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate are central excipient candidates.
• The active ingredients have no meaningful modern composition-of-matter exclusivity.
• Orange Book and Paragraph IV mechanisms generally have limited relevance for an OTC monograph product.
• Generic and private-label entry risk is high, but pseudoephedrine controls create operational barriers.
• The strongest commercial opportunities are private label, premium smaller tablets, compliant blister packaging, and retailer-exclusive SKUs.
• The strongest defensible IP would cover controlled-release architecture, dissolution performance, or manufacturing rather than the active-ingredient combination.
• FDA labeling, OTC compliance, NSAID warnings, and pseudoephedrine sales restrictions are central to launch planning.

FAQs

Can naproxen sodium and pseudoephedrine hydrochloride be formulated as an immediate-release tablet?

Yes, but an immediate-release format would not provide the intended 12-hour pseudoephedrine exposure. It would require a different label and would compete with shorter-duration sinus products.

Which excipient is most important for pseudoephedrine extended release?

The release-controlling polymer is usually the most important excipient class. Hypromellose viscosity grade, polymer concentration, and matrix geometry can materially change the dissolution profile.

Is pseudoephedrine a stronger commercial asset than phenylephrine?

Pseudoephedrine generally has stronger established decongestant positioning, but retail restrictions increase purchase friction. Phenylephrine is easier to sell in some channels, although FDA has questioned its effectiveness as an oral nasal decongestant at the standard OTC dose.

Can a generic use different inactive ingredients from the branded product?

Yes. A generic or OTC equivalent can use different excipients if the product satisfies applicable FDA quality, labeling, performance, safety, and manufacturing requirements.

What is the best packaging format for a pseudoephedrine combination product?

A child-resistant bottle is economical for high-volume retail. Unit-dose blister packaging offers better dose tracking, moisture protection, and diversion control but has higher packaging cost.

References

1. DailyMed. (2024a). Aleve-D Sinus & Headache: Naproxen sodium and pseudoephedrine hydrochloride extended-release tablets, labeling. U.S. National Library of Medicine.

2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 330, 331, and 341: Over-the-counter drug products and cold, cough, allergy, bronchodilator, and antiasthmatic drug products. U.S. Government Publishing Office.

3. U.S. Drug Enforcement Administration. (2024). Combat Methamphetamine Epidemic Act requirements for retail pseudoephedrine sales. U.S. Department of Justice.

4. U.S. Food and Drug Administration. (2023). FDA proposes removing oral phenylephrine from the over-the-counter monograph as a nasal decongestant. U.S. Department of Health and Human Services.